The E3 Ubiquitin-Protein Ligase Cullin 3 Regulates HIV-1 Transcription.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 18 08 2020
accepted: 28 08 2020
entrez: 5 9 2020
pubmed: 5 9 2020
medline: 15 4 2021
Statut: epublish

Résumé

The infectious life cycle of the human immunodeficiency virus type 1 (HIV-1) is characterized by an ongoing battle between a compendium of cellular proteins that either promote or oppose viral replication. On the one hand, HIV-1 utilizes dependency factors to support and sustain infection and complete the viral life cycle. On the other hand, both inducible and constitutively expressed host factors mediate efficient and functionally diverse antiviral processes that counteract an infection. To shed light into the complex interplay between HIV-1 and cellular proteins, we previously performed a targeted siRNA screen to identify and characterize novel regulators of viral replication and identified Cullin 3 (Cul3) as a previously undescribed factor that negatively regulates HIV-1 replication. Cul3 is a component of E3-ubiquitin ligase complexes that target substrates for ubiquitin-dependent proteasomal degradation. In the present study, we show that Cul3 is expressed in HIV-1 target cells, such as CD4+ T cells, monocytes, and macrophages and depletion of Cul3 using siRNA or CRISPR/Cas9 increases HIV-1 infection in immortalized cells and primary CD4+ T cells. Conversely, overexpression of Cul3 reduces HIV-1 infection in single replication cycle assays. Importantly, the antiviral effect of Cul3 was mapped to the transcriptional stage of the viral life cycle, an effect which is independent of its role in regulating the G1/S cell cycle transition. Using isogenic viruses that only differ in their promotor region, we find that the NF-κB/NFAT transcription factor binding sites in the LTR are essential for Cul3-dependent regulation of viral gene expression. Although Cul3 effectively suppresses viral gene expression, HIV-1 does not appear to antagonize the antiviral function of Cul3 by targeting it for degradation. Taken together, these results indicate that Cul3 is a negative regulator of HIV-1 transcription which governs productive viral replication in infected cells.

Identifiants

pubmed: 32882949
pii: cells9092010
doi: 10.3390/cells9092010
pmc: PMC7564853
pii:
doi:

Substances chimiques

CUL3 protein, human 0
Cullin Proteins 0
NF-kappa B 0
NFATC Transcription Factors 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA030199
Pays : United States
Organisme : NIAID NIH HHS
ID : P50 AI150476
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI124843
Pays : United States

Références

J Virol. 2007 Jun;81(11):6043-56
pubmed: 17376917
J Virol. 1995 May;69(5):2765-75
pubmed: 7707499
Curr Opin HIV AIDS. 2011 Jan;6(1):12-8
pubmed: 21242888
Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12153-8
pubmed: 14514886
Cell Host Microbe. 2010 Jul 22;8(1):55-67
pubmed: 20638642
Biomolecules. 2014 Oct 13;4(4):897-930
pubmed: 25314029
Genome Biol. 2011;12(4):220
pubmed: 21554755
Nature. 2011 Dec 21;481(7381):365-70
pubmed: 22190034
Elife. 2019 Feb 05;8:
pubmed: 30717826
Nature. 1989 May 4;339(6219):70-3
pubmed: 2654643
PLoS Pathog. 2009 May;5(5):e1000437
pubmed: 19478882
J Virol. 1998 Mar;72(3):2280-8
pubmed: 9499087
Cell Rep. 2015 Feb 3;10(4):586-99
pubmed: 25620704
Cell Host Microbe. 2008 Nov 13;4(5):495-504
pubmed: 18976975
Cell. 1988 Jun 3;53(5):827-36
pubmed: 2836068
Mol Cell. 2012 Jun 29;46(6):847-58
pubmed: 22578813
Cell Rep. 2016 Oct 25;17(5):1438-1452
pubmed: 27783955
Mol Cell. 1998 Mar;1(4):565-74
pubmed: 9660940
Nat Commun. 2016 Sep 19;7:12810
pubmed: 27641145
Proc Natl Acad Sci U S A. 2016 May 10;113(19):5311-6
pubmed: 27114546
J Cancer. 2015 Jan 16;6(3):233-42
pubmed: 25663940
EMBO J. 1995 Apr 3;14(7):1552-60
pubmed: 7729429
J Virol. 1994 Oct;68(10):6820-3
pubmed: 8084021
J Thorac Oncol. 2011 Sep;6(9):1521-9
pubmed: 21795997
Cell Microbiol. 2012 Nov;14(11):1745-56
pubmed: 22776683
Science. 2008 Feb 15;319(5865):921-6
pubmed: 18187620
Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7298-302
pubmed: 8346247
Front Microbiol. 2014 Aug 26;5:450
pubmed: 25206352
Genes Dev. 1999 Sep 15;13(18):2375-87
pubmed: 10500095
Nat Commun. 2017 Oct 27;8(1):1150
pubmed: 29074978
J Biol Chem. 1993 Mar 25;268(9):6677-88
pubmed: 8454640
Nat Med. 2003 Jun;9(6):727-8
pubmed: 12754504
Cell Rep. 2018 Feb 27;22(9):2493-2503
pubmed: 29490283
Biol Open. 2012 Feb 15;1(2):82-91
pubmed: 23213400
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6626-33
pubmed: 23542380
AIDS Res Hum Retroviruses. 2015 Jan;31(1):4-12
pubmed: 25287643
Blood. 2009 Jan 1;113(1):58-65
pubmed: 18849485
EMBO J. 2000 Jul 3;19(13):3475-84
pubmed: 10880460
J Biol Chem. 1996 Sep 13;271(37):22479-86
pubmed: 8798413
Cell Host Microbe. 2015 Sep 9;18(3):345-53
pubmed: 26355217
J Biol Chem. 2017 Dec 22;292(51):21117-21127
pubmed: 29079575
Cell Chem Biol. 2018 Jan 18;25(1):36-49
pubmed: 29153851
Cell. 1989 Oct 20;59(2):273-82
pubmed: 2478293
AIDS. 1988 Jun;2(3):185-93
pubmed: 2840098
Immunol Rev. 2012 Mar;246(1):286-310
pubmed: 22435562
J Virol. 1989 Jun;63(6):2557-66
pubmed: 2542571
Annu Rev Biochem. 1998;67:1-25
pubmed: 9759480
J Virol. 1994 May;68(5):3343-53
pubmed: 8151793
Mol Cell Biol. 1990 May;10(5):2327-34
pubmed: 2183031
Nat Biotechnol. 2015 Sep;33(9):985-989
pubmed: 26121415
Semin Cell Dev Biol. 2019 Sep;93:100-110
pubmed: 30586619
Cell. 2008 Oct 3;135(1):49-60
pubmed: 18854154
Immunity. 1997 Mar;6(3):235-44
pubmed: 9075924
Mol Cell. 2009 Oct 9;36(1):131-40
pubmed: 19818716
Cold Spring Harb Perspect Med. 2012 May;2(5):a006940
pubmed: 22553496
Front Immunol. 2018 Dec 06;9:2876
pubmed: 30574147
Viruses. 2017 Oct 31;9(11):
pubmed: 29088112
Oncogene. 1999 Nov 18;18(48):6829-34
pubmed: 10597293
Br Med Bull. 2001;58:43-59
pubmed: 11714623
Science. 1986 May 9;232(4751):755-9
pubmed: 3008338
Nat Rev Mol Cell Biol. 2005 Jan;6(1):9-20
pubmed: 15688063
J Biol Chem. 2004 Jul 23;279(30):31304-11
pubmed: 15131130
J Virol. 2012 Mar;86(5):2715-28
pubmed: 22190722
Biochim Biophys Acta Rev Cancer. 2018 Jan;1869(1):11-28
pubmed: 29128526
Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):E3921-30
pubmed: 27335459
Cell Host Microbe. 2018 Jan 10;23(1):14-26
pubmed: 29324227
Cell Host Microbe. 2015 Apr 8;17(4):489-99
pubmed: 25856754

Auteurs

Simon Langer (S)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Boehringer Ingelheim Pharma GmbH & Co. KG, 55216 Ingelheim am Rhein, Germany.

Xin Yin (X)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.

Arturo Diaz (A)

Department of Biology, La Sierra University, Riverside, CA 92515, USA.
The Nomis Center for Immunobiology and Microbial Pathogenesis, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Alex J Portillo (AJ)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Atara Biotherapeutics, Inc., Thousand Oaks, CA 91320, USA.

David E Gordon (DE)

Department of Cellular & Molecular Pharmacology, University of California, San Francisco, CA 94143, USA.
Gladstone Institutes, San Francisco, CA 94158, USA.
Quantitative Biosciences Institute (QBI), San Francisco, CA 94158, USA.

Umu H Rogers (UH)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
UC San Diego School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.

John M Marlett (JM)

The Nomis Center for Immunobiology and Microbial Pathogenesis, The Salk Institute for Biological Studies, La Jolla, CA 92037, USA.

Nevan J Krogan (NJ)

Department of Cellular & Molecular Pharmacology, University of California, San Francisco, CA 94143, USA.
Gladstone Institutes, San Francisco, CA 94158, USA.
Quantitative Biosciences Institute (QBI), San Francisco, CA 94158, USA.

John A T Young (JAT)

Roche Pharma Research and Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland.

Lars Pache (L)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.

Sumit K Chanda (SK)

Immunity and Pathogenesis Program, Infectious and Inflammatory Disease Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH